{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:34:41Z","timestamp":1778790881570,"version":"3.51.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T00:00:00Z","timestamp":1568764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008478","name":"Instituto Nacional del C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02213","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T13:45:12Z","timestamp":1568814312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR\u03b2 Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood"],"prefix":"10.3389","volume":"10","author":[{"given":"Mariana","family":"Aris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia In\u00e9s","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heli Magal\u00ed","family":"Garcia Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibel","family":"Carri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Podaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Alejandra","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Rotondaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Bentivegna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Marcela","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Mordoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF -mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF -mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann Transl Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"B14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3389\/fimmu.2017.00625","article-title":"Phase II study of adjuvant immunotherapy with the CSF-470 vaccine plus bacillus calmette\u2013guerin plus recombinant human granulocyte macrophage-colony stimulating factor vs medium-dose interferon alpha 2B in stages IIB, IIC, and III cutaneous melanoma patients","volume":"8","author":"Mordoh","year":"2017","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3389\/fimmu.2018.02531","article-title":"Dissecting the immune stimulation promoted by CSF-470 vaccine plus adjuvants in cutaneous melanoma patients: long term antitumor immunity and short term release of acute inflammatory reactants","volume":"9","author":"Pampena","year":"2018","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3389\/fimmu.2018.00955","article-title":"Changes in the TCR\u03b2 repertoire and tumor immune signature from a cutaneous melanoma patient immunized with the CSF-470 vaccine: a case report","volume":"9","author":"Aris","year":"2018","journal-title":"Front Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.cji.0000208258.79005.5f","article-title":"A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients","volume":"29","author":"Barrio","year":"2006","journal-title":"J Immunother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2013.00098","article-title":"Modeling the Mycobacterium tuberculosis granuloma \u2013 the critical battlefield in host immunity and disease","volume":"4","author":"Guirado","year":"2013","journal-title":"Front Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/path.1906","article-title":"New insights into the function of granulomas in human tuberculosis","volume":"208","author":"Ulrichs","year":"2006","journal-title":"J Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fimmu.2015.00144","article-title":"Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report","volume":"6","author":"Aris","year":"2015","journal-title":"Front Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.4049\/jimmunol.178.5.3161","article-title":"Mycobacterial lipomannan induces granuloma macrophage fusion via a TLR2-dependent, ADAM9- and beta1 integrin-mediated pathway","volume":"178","author":"Puissegur","year":"2007","journal-title":"J Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/path.2092","article-title":"Langhans giant cells from M. tuberculosis -induced human granulomas cannot mediate mycobacterial uptake","volume":"211","author":"Lay","year":"2007","journal-title":"J Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/cimm.1998.1352","article-title":"Multinucleated giant cell formation induced by IFN-(gamma)\/IL-3 is associated with restriction of virulent Mycobacterium tuberculosis cell to cell invasion in human monocyte monolayers","volume":"188","author":"Byrd","year":"1998","journal-title":"Cell Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3389\/fimmu.2017.01342","article-title":"Early events of the reaction elicited by CSF-470 melanoma vaccine plus adjuvants: an in vitro analysis of immune recruitment and cytokine releasE","volume":"8","author":"Pampena","year":"2017","journal-title":"Front Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/DAD.0b013e3181b34a19","article-title":"Cutaneous metastases of malignant melanoma: a clinicopathologic study of 192 cases with emphasis on the morphologic spectrum","volume":"32","author":"Plaza","year":"2010","journal-title":"Am J Dermatopathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00002371-200001000-00004","article-title":"Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma","volume":"23","author":"Kawakami","year":"2000","journal-title":"J Immunother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1158\/1078-0432.CCR-16-2680","article-title":"Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression","volume":"23","author":"Parkhurst","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12896-017-0379-9","article-title":"Overview of methodologies for T-cell receptor repertoire analysis","volume":"17","author":"Rosati","year":"2017","journal-title":"BMC Biotechnol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1158\/2326-6066.CIR-14-0154","article-title":"Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma","volume":"2","author":"Bajor","year":"2014","journal-title":"Cancer Immunol Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"eaal2568","DOI":"10.1126\/sciimmunol.aal2568","article-title":"Tracking the fate and origin of clinically relevant adoptively transferred CD8+ T cells in vivo","volume":"2","author":"Chapuis","year":"2017","journal-title":"Sci Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.4049\/jimmunol.168.8.4231","article-title":"Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity","volume":"168","author":"Valmori","year":"2002","journal-title":"J Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1158\/1078-0432.CCR-16-1708","article-title":"Rapid and continued T-cell differentiation into long-term effector and memory stem cells in vaccinated melanoma patients","volume":"23","author":"Gannon","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","article-title":"Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases","volume":"71","author":"Corbi\u00e8re","year":"2011","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00262-018-2152-x","article-title":"Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination","volume":"67","author":"Takeda","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1346764","DOI":"10.1080\/2162402X.2017.1346764","article-title":"Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma","volume":"6","author":"Tsuchiya","year":"2017","journal-title":"Oncoimmunology."},{"key":"B37","doi-asserted-by":"publisher","first-page":"122092","DOI":"10.1172\/jci.insight.122092","article-title":"T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma","volume":"3","author":"Hopkins","year":"2018","journal-title":"JCI Insight."},{"key":"B38","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1372081","DOI":"10.1080\/2162402X.2017.1372081","article-title":"Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: results of a phase I vaccine trial","volume":"7","author":"Chung","year":"2018","journal-title":"Oncoimmunology."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02213\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T13:45:17Z","timestamp":1568814317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02213\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2019.02213"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02213","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]},"article-number":"2213"}}